Cognitive Impact in Patients With COVID-19 Infection

Completed

• Conditions: Cognitive Impairment; COVID-19 Respiratory Infection

• Registration Number: NCT05293561
• Lead Sponsor: Assiut University

Brief Summary

SARS-COV-2 (severe acute respiratory syndrome- corona virus - 2) infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological and psychosocial impairments. Literature regarding cognitive impact of COVID-19 is still limited.

Objective: evaluation of cognitive function, anxiety and depression among patients with Coronavirus disease 19.

Detailed Description

COVID-19 results in a variety of symptoms with multi-organ affection, including fever, cough; grave respiratory symptoms, gastrointestinal manifestations and fatigue. As more is learned, neurological and psychological symptoms appear to manifest in a large subscale of patients. Headache, dizziness and even a cerebrovascular event have been reported. Anosmia and ageusia reported as early indicators of SARS-CoV-2 infection, suggesting that early neurological involvement may be relevant.

Public health emergencies as COVID-19 are likely to cause adverse neuropsychiatric impacts. Cognitive impairments after SARS-COV-2 infection were noticed, COVID-19 patients complain of poor concentration, declined memory, and insomnia, as well as anxiety and depression symptoms.

The battle against COVID-19 is still continuing worldwide. People's adherence to confinement regulations and response to vaccination campaigns is essential, which is largely affected by their knowledge, attitudes, and practices towards COVID-19. Home isolation and social distancing are also associated with fear, frustrations, uncertainty, anxiety and depressive symptoms.

During the acute phase of COVID-19 infection, about 36% of cases develop neurological symptoms of which 25% can be attributed to the direct involvement of the central nervous system. Patients who show neurological symptoms included cases with or without pre-existing neurological disorders. While on intensive care units, patients showed agitation, confusion, and corticospinal tract signs such as enhanced tendon reflexes and clonus. COVID-19 can further lead to changes of coagulation and, in particular, to inflammation-induced disseminated intravascular coagulation (DIC).

Study Timeline

• Study Start: 2021-06-01
• Study First Submitted: 2022-03-22
• Study First Submitted QC: 2022-03-22
• Study First Posted: 2022-03-24
• Primary Completion: 2022-10-01
• Study Completion: 2022-12-01
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-30
• Last Update Posted: 2024-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• COVID-19 patients diagnosed using Real Time-Polymerase Chain Reaction to confirm the diagnosis

Exclusion Criteria

• neurological disorders, psychological disorders, dementia, Alzheimer's disease, end-organ failure conditions

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive impairment	1 month	degree of affection in cognition due to COVID-19 infection

Secondary Outcome Measures

Name	Time	Method
Level of Anxiety and depression among COVID-19 cases	1 month	Level of Anxiety and depression among COVID-19 cases

Trial Locations

Locations (1)

Assiut University; 🇪🇬 Assiut, Egypt